Caris Life Sciences, Inc. (CAI) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
CAI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Caris Life Sciences, Inc. (CAI) trades at a price-to-earnings ratio of -5.9x, with a stock price of $19.13 and trailing twelve-month earnings per share of $-0.32.
The current P/E is 123% below its 5-year average of 25.4x. Over the past five years, CAI's P/E has ranged from a low of 9.5x to a high of 41.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CAI trades at a 127% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, CAI trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CAI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CAI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $22B | 26.2Lowest | 6.18 | +171%Best | |
| $4B | 40.4 | 1.14Best | -10% | |
| $176B | 26.7 | 12.62 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CAI Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $30.25 | $0.73 | 41.3x | +63% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $26.72 | $2.82 | 9.5x | -63% |
Average P/E for displayed period: 25.4x
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAI — Frequently Asked Questions
Quick answers to the most common questions about buying CAI stock.
Is CAI stock overvalued or undervalued?
CAI trades at -5.9x P/E, below its 5-year average of 25.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CAI's valuation compare to peers?
Caris Life Sciences, Inc. P/E of -5.9x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is CAI's PEG ratio?
CAI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.